420 related articles for article (PubMed ID: 25987766)
1. MET inhibitors for treatment of advanced hepatocellular carcinoma: A review.
Qi XS; Guo XZ; Han GH; Li HY; Chen J
World J Gastroenterol; 2015 May; 21(18):5445-53. PubMed ID: 25987766
[TBL] [Abstract][Full Text] [Related]
2. Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
Zhao S; Wu W; Jiang H; Ma L; Pan C; Jin C; Mo J; Wang L; Wang K
Front Immunol; 2021; 12():731527. PubMed ID: 34804015
[TBL] [Abstract][Full Text] [Related]
3. Tivantinib: critical review with a focus on hepatocellular carcinoma.
Rota Caremoli E; Labianca R
Expert Opin Investig Drugs; 2014 Nov; 23(11):1563-74. PubMed ID: 25307444
[TBL] [Abstract][Full Text] [Related]
4. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.
Rimassa L; Assenat E; Peck-Radosavljevic M; Pracht M; Zagonel V; Mathurin P; Rota Caremoli E; Porta C; Daniele B; Bolondi L; Mazzaferro V; Harris W; Damjanov N; Pastorelli D; Reig M; Knox J; Negri F; Trojan J; López López C; Personeni N; Decaens T; Dupuy M; Sieghart W; Abbadessa G; Schwartz B; Lamar M; Goldberg T; Shuster D; Santoro A; Bruix J
Lancet Oncol; 2018 May; 19(5):682-693. PubMed ID: 29625879
[TBL] [Abstract][Full Text] [Related]
5. Tivantinib in hepatocellular carcinoma.
Trojan J; Zeuzem S
Expert Opin Investig Drugs; 2013 Jan; 22(1):141-7. PubMed ID: 23167786
[TBL] [Abstract][Full Text] [Related]
6. Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma.
Bouattour M; Raymond E; Qin S; Cheng AL; Stammberger U; Locatelli G; Faivre S
Hepatology; 2018 Mar; 67(3):1132-1149. PubMed ID: 28862760
[TBL] [Abstract][Full Text] [Related]
7. Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma.
Gao J; Inagaki Y; Song P; Qu X; Kokudo N; Tang W
Pharmacol Res; 2012 Jan; 65(1):23-30. PubMed ID: 22138044
[TBL] [Abstract][Full Text] [Related]
8. Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers.
Rimassa L; Santoro A; Daniele B; Germano D; Gasbarrini A; Salvagni S; Masi G; Abbadessa G; Lamar M; Goldberg T; Porta C
Tumori; 2015; 101(2):139-43. PubMed ID: 25838254
[TBL] [Abstract][Full Text] [Related]
9. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
Santoro A; Rimassa L; Borbath I; Daniele B; Salvagni S; Van Laethem JL; Van Vlierberghe H; Trojan J; Kolligs FT; Weiss A; Miles S; Gasbarrini A; Lencioni M; Cicalese L; Sherman M; Gridelli C; Buggisch P; Gerken G; Schmid RM; Boni C; Personeni N; Hassoun Z; Abbadessa G; Schwartz B; Von Roemeling R; Lamar ME; Chen Y; Porta C
Lancet Oncol; 2013 Jan; 14(1):55-63. PubMed ID: 23182627
[TBL] [Abstract][Full Text] [Related]
10. Medical Systemic Therapies for Hepatocellular Carcinoma: Clinical Perspectives and Safety Profile.
Facciorusso A; Antonino M; Del Prete V; Amoruso A; Neve V; Barone M
Curr Drug Saf; 2015; 10(3):202-7. PubMed ID: 25994808
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib: from literature to clinical practice.
Di Marco V; De Vita F; Koskinas J; Semela D; Toniutto P; Verslype C
Ann Oncol; 2013 Apr; 24 Suppl 2():ii30-7. PubMed ID: 23715941
[TBL] [Abstract][Full Text] [Related]
12. Tivantinib (ARQ197) in hepatocellular carcinoma.
Porta C; Giglione P; Ferrari A; Reversi F; Liguigli W; Imarisio I; Ganini C
Expert Rev Anticancer Ther; 2015 Jun; 15(6):615-22. PubMed ID: 26035719
[TBL] [Abstract][Full Text] [Related]
13. Tivantinib for the treatment of hepatocellular carcinoma.
Best J; Schotten C; Lohmann G; Gerken G; Dechêne A
Expert Opin Pharmacother; 2017 May; 18(7):727-733. PubMed ID: 28414564
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
15. Met as a therapeutic target in HCC: facts and hopes.
Giordano S; Columbano A
J Hepatol; 2014 Feb; 60(2):442-52. PubMed ID: 24045150
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma.
Soto-Perez-de-Celis E; Aguiar PN; Cordón ML; Chavarri-Guerra Y; Lopes GL
J Natl Compr Canc Netw; 2019 Jun; 17(6):669-675. PubMed ID: 31200357
[TBL] [Abstract][Full Text] [Related]
17. Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib.
Personeni N; Pressiani T; Rimassa L
Future Oncol; 2019 Jul; 15(21):2449-2462. PubMed ID: 31204849
[TBL] [Abstract][Full Text] [Related]
18. Trends in the development of MET inhibitors for hepatocellular carcinoma.
Okuma HS; Kondo S
Future Oncol; 2016 May; 12(10):1275-86. PubMed ID: 26984595
[TBL] [Abstract][Full Text] [Related]
19. Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib.
Rimassa L; Abbadessa G; Personeni N; Porta C; Borbath I; Daniele B; Salvagni S; Van Laethem JL; Van Vlierberghe H; Trojan J; De Toni EN; Weiss A; Miles S; Gasbarrini A; Lencioni M; Lamar ME; Wang Y; Shuster D; Schwartz BE; Santoro A
Oncotarget; 2016 Nov; 7(45):72622-72633. PubMed ID: 27579536
[TBL] [Abstract][Full Text] [Related]
20. Novel drugs in clinical development for hepatocellular carcinoma.
Waidmann O; Trojan J
Expert Opin Investig Drugs; 2015; 24(8):1075-82. PubMed ID: 26108356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
